Halozyme Therapeutics HALO Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's total liabilities & equity?
- Halozyme Therapeutics (HALO) reported total liabilities & equity of $2.67B in Q1 2026.
- How has Halozyme Therapeutics's total liabilities & equity changed year-over-year?
- Halozyme Therapeutics's total liabilities & equity increased by 21.7% year-over-year, from $2.2B to $2.67B.
- What is the long-term trend for Halozyme Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's total liabilities & equity has grown at a 34.2% compound annual growth rate (CAGR), from $579.92M to $2.53B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.